Engineered immune cells take on tough lymphoma in new trial
NCT ID NCT07319676
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a personalized CAR T-cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. Patients' own immune cells are collected, modified to target cancer cells, and infused back. The trial has two phases: first to find the safest dose, then to check how well it works in 30 participants aged 10 to 80.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CAR T-cells (Epo-R-CD19 CAR T with or without CD22 CAR T)
What this could lead to
If successful, this could offer a new treatment option for patients with hard-to-treat B-cell lymphoma, potentially leading to longer remission.
What could go wrong
This is an early-phase trial with only 30 participants, so results may not apply to everyone. There are risks of serious side effects like cytokine release syndrome (CRS) and neurological issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National University Hospital
RECRUITINGSingapore, Singapore, 119228, Singapore
Contact Phone: •••-•••-••••
Contact